mRNA-derived Lung Cancer Vaccine BI 1361849

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A non-small cell lung cancer (NSCLC) vaccine containing six modified mRNAs, which encode six different NSCLC associated antigens, with potential antitumor and immunomodulatory activities. Upon intradermal administration, mRNA-derived lung cancer vaccine BI 1361849 may stimulate the immune system to mount both humoral and cellular responses against NSCLC cells. The six tumor-associated antigens (TAAs) encoded by these mRNAs are frequently expressed by NSCLC cells and are minimally expressed or absent in normal, healthy cells.

**Synonyms:** - BI 1361849 - BI1361849 - CV9202